CL2013000868A1 - Isolated antibody that binds to the human cytomegalovirus (hcmv) complex or hcmv gh; nucleic acid encoding it; host cell; Method of production; composition that includes it; and its use to treat, inhibit or prevent hcmv infection. - Google Patents

Isolated antibody that binds to the human cytomegalovirus (hcmv) complex or hcmv gh; nucleic acid encoding it; host cell; Method of production; composition that includes it; and its use to treat, inhibit or prevent hcmv infection.

Info

Publication number: CL2013000868A1
Authority: CL; Chile
Prior art keywords: hcmv; binds; inhibit; treat; complex
Prior art date: 2010-09-29

Application number

CL2013000868A

Other languages

Spanish (es)

Inventor

Xiaocheng Chen

Mark S Dennis

Becket L Feierbach

Ashley E Fouts

Isidro Hotzel

Bing Li

Jo-Anne Hongo

Rajesh Vij

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-29

Filing date

2013-03-28

Publication date

2014-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45890018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000868(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-28 Application filed by Genentech Inc filed Critical Genentech Inc

2014-01-24 Publication of CL2013000868A1 publication Critical patent/CL2013000868A1/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C07K16/089—Cytomegalovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Mycology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CL2013000868A 2010-09-29 2013-03-28 Isolated antibody that binds to the human cytomegalovirus (hcmv) complex or hcmv gh; nucleic acid encoding it; host cell; Method of production; composition that includes it; and its use to treat, inhibit or prevent hcmv infection. CL2013000868A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US38773510P	2010-09-29	2010-09-29
US38772510P	2010-09-29	2010-09-29
US201161504056P	2011-07-01	2011-07-01

Publications (1)

Publication Number	Publication Date
CL2013000868A1 true CL2013000868A1 (en)	2014-01-24

Family

ID=45890018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013000868A CL2013000868A1 (en)	2010-09-29	2013-03-28	Isolated antibody that binds to the human cytomegalovirus (hcmv) complex or hcmv gh; nucleic acid encoding it; host cell; Method of production; composition that includes it; and its use to treat, inhibit or prevent hcmv infection.

Country Status (21)

Country	Link
US (2)	US20120082666A1 (en)
EP (1)	EP2621533A4 (en)
JP (1)	JP2014501491A (en)
KR (1)	KR20130112879A (en)
CN (2)	CN104945505A (en)
AR (1)	AR083214A1 (en)
AU (1)	AU2011312425A1 (en)
BR (1)	BR112013007514A2 (en)
CA (1)	CA2811087A1 (en)
CL (1)	CL2013000868A1 (en)
CO (1)	CO6690799A2 (en)
CR (1)	CR20130133A (en)
EA (1)	EA201390467A1 (en)
EC (1)	ECSP13012536A (en)
IL (1)	IL225389A0 (en)
MA (1)	MA34541B1 (en)
MX (1)	MX2013002960A (en)
PE (1)	PE20140195A1 (en)
PH (1)	PH12013500616A1 (en)
SG (1)	SG188657A1 (en)
WO (1)	WO2012047732A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20140138971A (en) *	2012-03-28	2014-12-04	제넨테크, 인크.	Anti-hcmv idiotypic antibodies and uses thereof
WO2014099908A1 (en) *	2012-12-17	2014-06-26	Genentech, Inc.	Methods for inhibiting viral infection in transplant patients
US9657098B2 (en)	2013-03-15	2017-05-23	Intrinsic Lifesciences, Llc	Anti-hepcidin antibodies and uses thereof
MX2015016978A (en)	2013-06-10	2016-04-25	Merck Sharp & Dohme	Cmv neutralizing antigen binding proteins.
ES2915378T3 (en)	2013-09-13	2022-06-22	Hoffmann La Roche	Methods for detecting and quantifying a host cell protein in cell lines
EP4331605A3 (en)	2013-09-13	2024-05-22	F. Hoffmann-La Roche AG	Methods and compositions comprising purified recombinant polypeptides
AU2015321462B2 (en)	2014-09-22	2020-04-30	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
IL257146B2 (en)	2015-08-21	2025-01-01	Hoffmann La Roche	Method for the reduction of host cell proteins in affinity chromatography
GB201607979D0 (en) *	2016-05-06	2016-06-22	Liverpool School Tropical Medicine	Monomeric proteins and uses thereof
AU2019364823B2 (en)	2018-10-25	2025-10-30	Km Biologics Co., Ltd.	Modified CMV gB protein and CMV vaccine including same
WO2023034950A2 (en) *	2021-09-03	2023-03-09	Icahn School Of Medicine At Mount Sinai	Anti-hcmv antibodies and antigen-binding fragments thereof
WO2024229365A1 (en) *	2023-05-03	2024-11-07	The University Of Chicago	Growth hormone targeting polypeptides
CN119269807A (en) *	2024-11-26	2025-01-07	华润昂德生物药业有限公司	A method for detecting the in vitro binding activity of EPO and its receptor EpoR based on SPR

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0683675A4 (en) *	1993-01-28	1997-05-21	Sandoz Pharmaceuticals Corp	Human monoclonal antibodies to cytomegalovirus.
WO1996006625A1 (en) *	1994-08-26	1996-03-07	Eli Lilly And Company	Antibody constructs with cdr switched variable regions
US6875433B2 (en) *	2002-08-23	2005-04-05	The United States Of America As Represented By The Secretary Of The Army	Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
US7491390B2 (en) *	2004-10-15	2009-02-17	Seattle Genetics, Inc.	Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
CA2618796C (en) *	2005-08-11	2018-01-02	Arpi Matossian-Rogers	Peptides for treatment and diagnosis of autoimmune disease
US20080003605A1 (en) *	2006-05-24	2008-01-03	The University Of Chicago	Microarray analysis of light chain variable gene expression and methods of use
EP3031469B1 (en) *	2006-06-07	2023-08-23	The Trustees Of Princeton University	Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US8153129B2 (en) *	2006-12-15	2012-04-10	Ribovax Biotechnologies S.A.	Antibodies against human cytimegalovirus (HCMV)
PE20141435A1 (en) *	2008-07-16	2014-10-22	Inst Research In Biomedicine	NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS

2011
- 2011-09-29 WO PCT/US2011/054092 patent/WO2012047732A2/en not_active Ceased
- 2011-09-29 SG SG2013022751A patent/SG188657A1/en unknown
- 2011-09-29 US US13/248,998 patent/US20120082666A1/en not_active Abandoned
- 2011-09-29 BR BR112013007514-7A patent/BR112013007514A2/en not_active IP Right Cessation
- 2011-09-29 EA EA201390467A patent/EA201390467A1/en unknown
- 2011-09-29 KR KR1020137007881A patent/KR20130112879A/en not_active Withdrawn
- 2011-09-29 MX MX2013002960A patent/MX2013002960A/en not_active Application Discontinuation
- 2011-09-29 CN CN201510363420.0A patent/CN104945505A/en active Pending
- 2011-09-29 PE PE2013000655A patent/PE20140195A1/en not_active Application Discontinuation
- 2011-09-29 CA CA2811087A patent/CA2811087A1/en not_active Abandoned
- 2011-09-29 EP EP11831352.7A patent/EP2621533A4/en not_active Withdrawn
- 2011-09-29 AU AU2011312425A patent/AU2011312425A1/en not_active Abandoned
- 2011-09-29 AR ARP110103598A patent/AR083214A1/en not_active Application Discontinuation
- 2011-09-29 CN CN201180057119.7A patent/CN103313727B/en not_active Expired - Fee Related
- 2011-09-29 JP JP2013531893A patent/JP2014501491A/en active Pending
- 2011-09-29 MA MA35760A patent/MA34541B1/en unknown
- 2011-09-29 PH PH1/2013/500616A patent/PH12013500616A1/en unknown
2013
- 2013-03-21 CR CR20130133A patent/CR20130133A/en unknown
- 2013-03-21 IL IL225389A patent/IL225389A0/en unknown
- 2013-03-28 CL CL2013000868A patent/CL2013000868A1/en unknown
- 2013-03-28 EC ECSP13012536 patent/ECSP13012536A/en unknown
- 2013-04-12 CO CO13095273A patent/CO6690799A2/en unknown
2014
- 2014-12-19 US US14/577,991 patent/US20150376265A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2621533A2 (en)	2013-08-07
CR20130133A (en)	2013-08-29
AR083214A1 (en)	2013-02-06
CO6690799A2 (en)	2013-06-17
JP2014501491A (en)	2014-01-23
WO2012047732A2 (en)	2012-04-12
CN104945505A (en)	2015-09-30
US20120082666A1 (en)	2012-04-05
CA2811087A1 (en)	2012-04-12
MX2013002960A (en)	2013-05-09
WO2012047732A3 (en)	2013-05-30
SG188657A1 (en)	2013-05-31
CN103313727A (en)	2013-09-18
IL225389A0 (en)	2013-06-27
EP2621533A4 (en)	2015-06-17
AU2011312425A1 (en)	2013-04-11
ECSP13012536A (en)	2013-06-28
PE20140195A1 (en)	2014-02-24
CN103313727B (en)	2015-07-22
HK1189501A1 (en)	2014-06-13
MA34541B1 (en)	2013-09-02
BR112013007514A2 (en)	2019-09-24
EA201390467A1 (en)	2013-11-29
PH12013500616A1 (en)	2013-06-03
US20150376265A1 (en)	2015-12-31
KR20130112879A (en)	2013-10-14

Similar Documents

Publication	Publication Date	Title
CL2013000868A1 (en)	2014-01-24	Isolated antibody that binds to the human cytomegalovirus (hcmv) complex or hcmv gh; nucleic acid encoding it; host cell; Method of production; composition that includes it; and its use to treat, inhibit or prevent hcmv infection.
CL2013000545A1 (en)	2014-09-26	Anti-ox40 antibody; nucleic acid encoding it; host cell; Method of production; and its use to treat cancer or an autoimmune disease.
CL2014000958A1 (en)	2014-08-29	Antibody polypeptides that antagonize cd4ol; nucleic acid encoding said antibody; vector and host cell that comprise it; pharmaceutical composition; use of said polypeptides to treat immune disease.
CL2013003336A1 (en)	2014-06-06	Human anti-cgrp antibody; nucleic acid encoding it; vector; host cell; Method of production; pharmaceutical and diagnostic composition that includes it; and its therapeutic use
BR112015010817A2 (en)	2017-11-28	anti-hemagglutinin antibodies, method of treating, inhibiting or preventing infections, composition, pharmaceutical composition, nucleic acid, host cell, antibody production method and use of anti-hemagglutinin antibody
CA2865594C (en)	2021-07-27	Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BR112014004168A2 (en)	2017-12-12	bispecific antibody, pharmaceutical composition, use of bispecific antibody, prokaryotic or eukaryotic host cell, antibody production method and invention
CL2007001488A1 (en)	2008-01-04	Human or humanized anti-integrin alpha5beta1 antibody; nucleic acid encoding it; vector and host cell that comprise it; production procedure; pharmaceutical composition that includes it; and its use to prevent or treat disorders associated with integrin.
CL2016001340A1 (en)	2016-10-28	Neutralizing antibodies to human cytomegalovirus and their use (divisional sol. No. 1293-14, which is also divisional sol. No. 84-11).
CL2015000665A1 (en)	2015-06-26	Glucagon analog compound useful for preventing weight gain or promoting weight loss; nucleic acid encoding it; vector; host cell; kit; and production procedure.
EA201300256A1 (en)	2013-08-30	ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH-3 FACTOR (HER3)
AR091098A1 (en)	2015-01-14	ANTIBODIES AND IMMUNOCATED TO Ly6E AND METHODS OF USE
CL2013000930A1 (en)	2014-03-28	Antibody for interleukin 17 (il-17); use of said antibody to treat psoriasis using il-17 antagonists.
CL2013001625A1 (en)	2014-02-21	Binding protein that specifically binds to tnf-alpha; nucleic acid encoding it; vector; host cell; Method of production; pharmaceutical composition that includes it; and its use to treat a disease or disorder associated with tnf-alpha.
CL2014000181A1 (en)	2014-07-25	Monoclonal antibody capable of inhibiting receptor dimerization for hepatocyte growth factor (c-met); isolated nucleic acid encoding it; vector and host cell that comprise it; process for the production of the antibody; use of the antibody to treat cancer (divisional of application 1296-11).
CL2011002756A1 (en)	2012-03-23	Antibody that binds to human or cynomolgus complement protein c3b; pharmaceutical composition, nucleic acid, vector and host cell comprising said antibody; use to treat age-related macular degeneration.
TN2014000438A1 (en)	2016-03-30	Anti-fcrn antibodies
BR112012027994A2 (en)	2017-03-21	isolated antibody, pharmaceutical composition, isolated nucleic acid, compositions, host cell, methods of treating multiple sclerosis, rheumatoid arthritis, osteolytic bone loss and cancer
CL2011002784A1 (en)	2012-08-31	Anti-egfl7 antibody; nucleic acid that encodes it; vector; host cell; Preparation method; composition comprising it, and its use to treat a tumor, cancer or a proliferative disorder.
BR112015029788A2 (en)	2017-09-26	hetero-multimer, isolated antibody construct, nucleic acid, host cell, method for preparing the hetero-multimer, pharmaceutical composition, method for treating a disease, use of the hetero-multimer, use of a therapeutic amount of the hetero-multimer, and method for reduce effector function of an antibody construct
CL2011002003A1 (en)	2012-05-25	Humanized antibody or fragments thereof, which bind to the epidermal growth factor receptor (egfr) in an aberrant expression or truncated egfr? 2-7; host cell; pharmaceutical composition comprising it; and its use to treat cancer.
EA201391577A1 (en)	2014-03-31	COMPOSITION INCLUDING AFLIBERTSEPT, FOLINIC ACID, 5-FLUOROURAL (5-FU) AND IRINOCETAN (FOLFIRI)
AR088322A1 (en)	2014-05-28	ANTI-HTRA1 ANTIBODIES AND METHODS OF USE
GB201003701D0 (en)	2010-04-21	System for the expression of a protein
BR112012032193A2 (en)	2019-09-24	phenylthioacetate compound, compositions and methods of use